

Detailed Table of Contents

	<i>Main Volume</i>	<i>Supple- ment</i>
Foreword	vii	vii
Preface	ix	ix
About the Authors	xxi	xv
Summary Table of Contents	xxix	xxiii
Chapter 1. An Introduction to Health Care Fraud and Abuse	1	1
I. Introduction	2	2
A. The Potential Risks	3	2
B. Exposure for Attorneys	14	8
C. Likelihood of Increased Enforcement Efforts in the Future	17	9
1. Pharmaceutical Fraud	20	11
2. Medicare Part D	23	11
3. State Enforcement	25	12
4. Private Enforcement	27	—
5. RACs, MEDICs, and ZPICs [New Topic]	—	14
6. Clinical Research Enforcement [New Topic]	—	15
7. Disclosure of Drug and Device Vendor Relationships [New Topic]	—	17
II. The Federal Fraud and Abuse Laws	27	18
A. The Anti-Kickback Statute	28	18
1. The Prohibitions	28	—
2. Exceptions and Safe Harbors	28	—
3. Special Fraud Alerts and Special Advisory Bulletins	33	—
4. Office of Inspector General Advisory Opinions	36	18
5. Other Guidance	38	19
6. Enforcement	41	21
B. The Stark Law	41	22
1. The Prohibitions	41	—
2. The Exceptions	44	22
a. Phase III Regulations and the Physician Fee Schedule Regulations [New Topic]	—	22

b. Stark Law Regulations in the 2009 IPPS Final Rule [New Topic]	—	24
c. Stark Law Provisions in the Patient Protection and Affordable Care Act [New Topic]	—	26
3. Advisory Opinions	47	28
4. Specialty Hospitals	49	28
5. Enforcement	49	29
C. False Claims Statutes	51	32
1. The False Claims Act	51	32
2. Other Statutes Prohibiting False Claims	57	—
D. Civil Monetary Penalties	58	33
1. The Prohibitions	58	33
2. Beneficiary Inducement	61	34
3. Special Advisory Bulletin on Beneficiary Inducement	63	—
4. Gainsharing	65	35
5. CMP Enforcement	68	36
E. Exclusion Authorities	69	40
1. Mandatory Exclusion	69	40
2. Permissive Exclusion	70	40
3. Special Advisory Bulletin on Exclusion	71	—
F. Federal All-Payor Statutes	73	—
III. State Laws	74	41
IV. Other Resources	77	42
A. Compliance Program Guidance	78	42
B. The OIG Work Plans [Amended Topic]	80	43
C. The OIG Semiannual Report	83	55
D. Enforcement Resources	84	56
1. The Provider Self-Disclosure Protocol	84	—
2. The Inspector General’s Open Letter on the CIA Process	85	—
3. 2006 Open Letter to Health Care Providers	86	—
4. 2008 Open Letter to Health Care Providers [New Topic]	—	56
5. 2009 Open Letter to Health Care Providers [New Topic]	—	56
6. Stark Self-Disclosure Protocol [New Topic]	—	57
E. Miscellaneous	87	57
V. Conclusion	87	—

Chapter 2. Federal Physician Self-Referral Restrictions

[Substitute Text]	—	59
I. Introduction	—	63
II. Historical Background	—	64
A. Legislative History	—	64
B. Regulatory History	—	66
1. Sanctions	—	66
2. Stark I	—	66
3. Stark II Proposed Rule	—	66
4. Stark II Final Rules	—	67
a. Phase I and II	—	67
b. Phase III Final Rule	—	67
c. CMS’s Approach to Drafting the Final Rules	—	68

5.	EHR Donation Final Rule	—	68
6.	Annual Rulemaking Cycle	—	68
C.	Patient Protection and Affordable Care Act	—	69
D.	Effective Dates	—	69
III.	Rulemaking Highlights	—	71
A.	Phase I Final Rule Highlights	—	71
1.	Significant Interpretations/Exceptions	—	71
2.	New Exceptions	—	72
3.	Key Statutory Terms	—	72
B.	Phase II Final Rule Highlights	—	72
1.	Significant Interpretations/Exceptions	—	72
2.	Statutory Exceptions	—	73
3.	New Exceptions	—	73
4.	Other	—	74
C.	Phase III Final Rule Highlights	—	74
1.	Significant Interpretations/Exceptions	—	74
a.	Indirect Compensation and the “Stand in the Shoes” Rule	—	74
b.	Exceptions Related to Various Forms of Physician Compensation	—	75
c.	Academic Medical Centers Exception	—	75
2.	Statutory Compensation Exceptions	—	75
3.	Compensation Exceptions Created by Regulation	—	75
D.	The Fee Schedule Rules	—	75
1.	The 2008 Rules.	—	75
2.	2009 IPFS Final Rule	—	76
3.	2009 MPFS Final Rule	—	76
4.	2010 MPFS Final Rule	—	76
IV.	General Prohibition and Key Statutory Terms	—	76
A.	The General Prohibition	—	76
B.	Key Statutory Terms	—	77
1.	Referral	—	77
2.	Entity	—	79
a.	Revised Definition of “Entity”	—	79
b.	Performing a DHS	—	80
3.	Financial Relationship	—	81
4.	Ownership or Investment Interest	—	81
a.	Direct Ownership or Investment Interest	—	81
b.	Indirect Ownership or Investment Interest	—	82
5.	Compensation Arrangement	—	82
6.	Remuneration	—	83
7.	Knowledge Standard	—	84
C.	Temporary Noncompliance Exception	—	85
D.	Alternative Method of Compliance With Signature Requirement	—	86
V.	Designated Health Services	—	87
A.	Listed Designated Health Services	—	87
B.	General Principles	—	87
C.	Radiology and Certain Other Imaging Services	—	88
D.	Outpatient Prescription Drugs	—	88
E.	Inpatient and Outpatient Hospital Services	—	88
VI.	Exceptions Related to Physician Compensation	—	89
A.	Introduction	—	89

B.	Volume or Value, Other Business Generated, Set in Advance, and Incident to Services and Supplies ...	—	89
1.	Volume or Value of Referrals	—	90
2.	Other Business Generated	—	90
3.	Set-in-Advance Test	—	91
a.	Percentage-Based Compensation and Productivity Bonuses	—	91
b.	Specific Formula	—	92
C.	Fair Market Value Definition	—	92
1.	Defining Fair Market Value	—	92
D.	Commercially Reasonable	—	95
E.	Directed Referrals	—	95
F.	Compensation to Physician Employees	—	95
1.	The Bona Fide Employment Exception	—	95
2.	Leased Employees	—	96
G.	Compensation to Physician Independent Contractors and Physicians in the Group	—	96
VII.	Indirect Compensation Definition and Exception	—	96
A.	Definitions	—	97
1.	Unbroken Chain Test	—	97
2.	Volume or Value or Other Business Generated Test	—	97
3.	Knowledge	—	98
B.	Exception for Indirect Compensation Arrangements	—	98
C.	The Physician “Stand in the Shoes” Rule	—	99
D.	Physician Organization	—	102
E.	The Grandfathering Provision	—	103
F.	DHS Entity “Stand in the Shoes”	—	104
VIII.	Definition of Group Practice and Exceptions for In-Office Ancillary Services and Physician Services	—	104
A.	Group Practice Definition	—	105
1.	Single Legal Entity	—	105
2.	Members of the Group	—	106
3.	Physician in the Group Practice	—	107
4.	The “Full Range of Services” Test	—	107
5.	The “Substantially All” Test	—	108
6.	The Unified Business Test	—	109
7.	Compensation: Profit Shares and Productivity Bonuses	—	110
8.	Group Practice Productivity Bonuses Related to “Incident to” Services and Supplies	—	111
9.	Foundation-Model Group Practices	—	112
B.	In-Office Ancillary Services Exception	—	113
1.	Scope of DHS That Can Be In-Office Ancillary Services	—	113
2.	Building Requirements	—	114
a.	Centralized Building	—	114
b.	Same Building	—	114
i.	Shared Space in “Same Building”	—	116
3.	Direct Supervision	—	117
4.	Billing Requirements	—	117
5.	Clarification of Interplay of In-Office Ancillary Services Exception and Reassignment and Purchased Diagnostic Tests	—	118

6.	Disclosure Requirements for Certain Imaging Services	—	118
C.	Exception for Physician Services	—	120
IX.	Managed Care Prepaid Plans and Risk-Sharing Exceptions ..	—	120
A.	The Prepaid Plan Exception	—	121
B.	Risk-Sharing Compensation Arrangements Exception ...	—	122
X.	Exception for Academic Medical Centers	—	122
A.	Teaching Hospital	—	123
B.	Referring Physician	—	123
C.	Compensation to Physicians in Academic Medical Centers	—	124
D.	Faculty Practice Plans	—	125
E.	Other AMC Exception Requirements	—	125
XI.	Other Exceptions Related to Both Ownership and Compensation	—	125
A.	Implants Furnished in Ambulatory Surgery Centers	—	125
B.	EPO and Other Dialysis-Related Outpatient Prescription Drugs	—	126
C.	Preventative Screening Tests, Vaccinations, and Immunizations	—	127
D.	Eyeglasses and Contact Lenses Following Cataract Surgery	—	127
E.	Intra-Family Referrals in Rural Areas	—	128
XII.	Ownership and Investment Interest Exceptions	—	129
A.	Publicly Traded Securities and Mutual Funds	—	130
B.	Specific Providers	—	130
1.	Hospital Ownership in Puerto Rico	—	130
2.	Rural Providers	—	130
3.	Hospital Ownership	—	131
a.	Specialty Hospital Moratorium	—	132
b.	PPACA Limitations on Physician-Owned Hospitals	—	133
i.	Basic Restrictions	—	133
ii.	Expansion of Physician-Owned Hospitals ..	—	135
iii.	Timing Issues	—	136
XIII.	Statutory Compensation Exceptions	—	136
A.	Rental of Office Space and Equipment	—	136
1.	Amendments	—	137
2.	Sharing Space or Equipment	—	138
3.	Holdover	—	138
4.	Early Termination	—	139
5.	Subleases	—	139
6.	“Per-Click” or Percentage Leases	—	139
7.	Capital Leases	—	139
B.	Personal Service Arrangement Exception	—	139
1.	Termination	—	140
2.	Master List of Contracts	—	140
3.	“Furnishing Services”	—	141
4.	Physician Incentive Plans	—	141
5.	Amendments	—	141
C.	Physician Recruitment	—	142
1.	Providers Subject to the Rule	—	142
2.	Income Guarantees and Allocated Costs	—	143
3.	Unavailability of Other Exceptions	—	143

4.	Relocation Requirement	—	144
5.	Geographic Area Served by the Hospital	—	144
6.	Referral Considerations	—	145
7.	Seeding Arrangements	—	145
	a. Flow of Funds	—	146
	b. Overhead Payments	—	147
	c. Practice Restrictions	—	148
8.	Anti-Kickback Compliance	—	148
9.	Written Agreement Signed by All Parties	—	148
10.	Other Issues	—	149
D.	Isolated Transactions	—	149
E.	Remuneration Unrelated to the Provision of Designated Health Services	—	150
F.	Certain Group Practice Arrangements With Hospitals	—	151
G.	Payments by a Physician for Items and Services	—	152
XIV.	Compensation Exceptions Created by Regulation	—	153
	A. Introduction	—	153
	B. The FMV Exception (Phase I)	—	153
	C. Charitable Donations by Physicians (Phase II)	—	153
	D. Nonmonetary Compensation (Phase I)	—	154
	E. Medical Staff Incidental Benefits (Phase I)	—	155
	F. Compliance Training (Phase I)	—	156
	G. Referral Services and Obstetrical Malpractice Insurance Subsidies (Phase II)	—	156
	H. Professional Courtesy (Phase II)	—	157
	I. Retention Payments in Underserved Areas (Phase II)	—	158
	J. Community-Wide Health Information Systems (Phase II)	—	159
	K. Electronic Health Records Exception	—	160
XV.	Application of Stark to State Medicaid Programs	—	161
XVI.	Reporting Requirements and Sanctions	—	162
	A. Reporting Requirements	—	162
	B. Sanctions	—	164
	C. Burden of Proof	—	164
	D. “Period of Disallowance”	—	165
XVII.	Differences Between the Stark Law and the Federal Anti-Kickback Statute	—	165
XVIII.	Stark Law Advisory Opinions	—	168
XIX.	Stark Law Advisory Opinions	—	169
XX.	Conclusion	—	170

Addendum to Chapter 2. Stark Phase III Regulation—

	Analysis and Comment	179	—
I.	Introduction	180	—
II.	Summary Comments and Highlights of Phase III	182	—
	A. Summary Comments	182	—
	B. Highlights and Issues	183	—
III.	General Prohibition and Key Statutory Terms	187	—
	A. Temporary Noncompliance Exception	187	—
	B. Entity	188	—
	C. Radiology and Certain Other Imaging Services	188	—
	D. Referral	189	—
	E. Ownership or Investment Interest	190	—

IV.	Indirect Compensation Definition and Exception and the “Stand in the Shoes” Rule	191	—
	A. The New “Stand in the Shoes” Rule	191	—
	B. The Sun-Setting Grandfather	192	—
	C. Comments	193	—
V.	Definition of Group Practice and In-Office Ancillary Services Exception	195	—
	A. Definitions	195	—
	B. In-Office Ancillary Services Exception	197	—
VI.	Exceptions Related to Various Forms of Physician Compensation	199	—
	A. Fair Market Value Definition and Exception	199	—
	B. Set in Advance and Incident to Services and Supplies	200	—
	C. Compensation to Physician Independent Contractors and Physicians in the Group	202	—
VII.	Physician Recruitment and Retention	203	—
	A. Physician Recruitment	204	—
	B. Retention Payments in Underserved Areas	206	—
	C. Comments	207	—
VIII.	Exception for Academic Medical Centers	208	—
IX.	Exceptions Related to Both Ownership and Compensation	210	—
	A. Physician Services	210	—
	B. Implants Furnished by an Ambulatory Surgery Center	210	—
	C. EPO and Other Dialysis-Related Outpatient Prescription Drugs	211	—
	D. Intra-Family Referrals in Rural Areas	211	—
X.	Ownership and Investment Interest Exceptions	212	—
	A. Publicly Traded Securities and Mutual Funds	212	—
	B. Rural Providers	212	—
	C. Whole Hospital Ownership	213	—
XI.	Statutory Compensation Exceptions	213	—
	A. Rental of Office Space and Equipment	213	—
	B. Personal Services	215	—
	C. Isolated Transactions	216	—
	D. Remuneration Unrelated to the Provision of Designated Health Services	216	—
	E. Certain Group Practice Arrangements with Hospitals	217	—
	F. Payments Made by a Physician for Items and Services ...	217	—
XII.	Compensation Exceptions Created by Regulation	217	—
	A. Charitable Donations by Physicians	218	—
	B. Non-Monetary Compensation	218	—
	C. Medical Staff Incidental Benefits	218	—
	D. Compliance Training	219	—
	E. Obstetrical Malpractice Insurance Subsidies	219	—
	F. Professional Courtesy	219	—
XIII.	Reporting and Recordkeeping Requirements	220	—
	A. Regulatory Requirements	220	—
	B. Disclosure of Financial Relationships Report	220	—

Chapter 3. The False Claims Act in Health Care		
Prosecutions: Application of the Substantive, <i>Qui Tam</i>, and Voluntary Disclosure Provisions	221	173
II. Congress’s 2009 Revisions to the False Claims Act		
[New Topic]	—	174
A. Post-1986 Case Law [New Topic]	—	177
1. The Link Between Claims and Presentment: <i>Totten</i> and <i>Allison Engine</i> [New Topic]	—	177
a. The D.C. Circuit’s Ruling in <i>Totten</i> [New Topic]	—	177
b. The Supreme Court’s Decision in <i>Allison Engine</i> [New Topic]	—	178
B. Reverse False Claims Case Law Developments [New Topic]	—	180
C. Statute of Limitations Case Law Developments [New Topic]	—	181
D. Whistleblower Retaliation Case Law Developments [New Topic]	—	182
E. Congress’s 2009 FCA Amendments [New Topic]	—	183
1. The Senate’s FCA Amendments [New Topic]	—	183
a. February 5, 2009, S. 386 [New Topic]	—	183
b. DOJ’s February 25, 2009, Letter [New Topic]	—	185
c. Senate Judiciary Committee Report (Mar. 2009) [New Topic]	—	189
d. April 22, 2009, Floor Statements [New Topic]	—	193
F. The House’s 2009 FCA Amendments (May 6, 2009) [New Topic]	—	197
1. Revisions to the Whistleblower Retaliation Provision [New Topic]	—	198
2. Statute of Limitations Provision [New Topic]	—	198
3. State Service Provision [New Topic]	—	199
4. Civil Investigative Demands [New Topic]	—	199
G. Expansion and Contraction of the FCA Resulting From the 2009 Amendments [New Topic]	—	201
1. Revisions to Subsections (a)(1)–(a)(2) (False Claims and Statements) and the Definition to “Claim” [New Topic]	—	202
2. Revisions to Subsection (a)(3) (Conspiracy) [New Topic]	—	202
3. Revisions to Subsection (a)(7) (Reverse False Claims) [New Topic]	—	202
4. Statute of Limitations [New Topic]	—	203
5. Whistleblower Retaliation [New Topic]	—	203
6. Projected Impact [New Topic]	—	203
I. Introduction	222	—
III. Construction of the “False” and “Knowing” Elements of the False Claims Act	226	204
A. Defining “Falsity” Under the FCA	228	204
1. Cases Establishing Falsity	229	204
a. Literal Falsity	229	—
b. Falsity by Implicit Certification	231	204
2. Cases in Which Courts Refused to Find That Defendant Submitted False or Fraudulent Claims		

or Statements	239	—
a. Literal Compliance	239	—
b. Non-Objective False Claims	240	—
B. The FCA “Knowing” Standard	242	208
1. Reckless Disregard	243	—
2. Deliberate Ignorance	246	—
3. Defenses Demonstrating Lack of Knowledge	249	208
a. Merely Negligent Conduct Does Not Result in Liability Under the FCA	251	208
b. The Government Cannot Predicate an FCA Action on Ambiguous Regulatory Guidance	253	—
c. Government Knowledge May Provide a Defense	254	—
d. The Defendants’ Reliance on Sound Legal Theory Negates an Inference of Fraud	257	211
C. FCA Damages and Civil Penalties [New Topic]	—	216
1. Kickbacks and Regulatory Violations [New Topic] ..	—	216
2. Determination of Number of Civil Penalties [New Topic]	—	219
a. CMS Form 1500 [New Topic]	—	220
b. UB-92 and Cost Reports [New Topic]	—	221
c. Dollar Amount of Civil Penalties Assessed Against Defendant [New Topic]	—	224
3. Constitutional Limitations on Civil Penalties [New Topic]	—	225
a. The Eighth Amendment [New Topic]	—	226
i. Extent and Harm of Defendant’s FCA Violations [New Topic]	—	226
ii. Comparable Penalties [New Topic]	—	228
iii. Class for Whom the FCA was Principally Designed [New Topic]	—	228
IV. Defending Against <i>Qui Tam</i> Actions	261	228
A. The Public Disclosure Jurisdictional Bar to <i>Qui Tam</i> Actions	261	—
B. History of the <i>Qui Tam</i> Public Disclosure Jurisdictional Bar	262	—
C. Case Law Construing the Public Disclosure Jurisdictional Bar	265	228
1. Meaning of “Public Disclosure”	266	228
a. The Majority Rule: Information is Public if It Is Disclosed to a Stranger to the Fraud	226	—
b. Ninth and Tenth Circuits’ Limitations of the Stranger-to-the-Fraud Rule: Requiring an Incentive to Reveal the Information or an Affirmative Disclosure	268	—
c. Disclosures to Federal Government Are Public ...	271	228
2. “Allegations” or “Transactions” of Fraud	272	—
a. Overview of the X+Y=Z Test	273	—
b. Application of the X+Y=Z Test When Information in the Public Domain Does Not Identify the Defendant	274	—
3. Hearing, Audit, Report, or Investigation	277	229
a. State Reports, Audits, or Investigations	278	229

b. Final Issuance or Completion of Report, Audit, or Investigation	280	—
4. “Based Upon” a Public Disclosure	281	—
5. The Original Source Provisions	285	229
a. Timing of the Relator’s Knowledge and Disclosure of Information	286	—
i. The D.C. and Sixth Circuits’ Rule That the Relator Must Be a True Whistleblower to Qualify as an Original Source	286	—
ii. The Second and Ninth Circuits’ Rule That the Relator Must Be the Source to the Entity that Made the Public Disclosure	289	—
iii. The Eighth Circuit’s Rule That the Relator Need Not Be a Whistleblower to Qualify as an Original Source	292	—
b. The Nature of the Relator’s Knowledge: The “Direct” and “Independent” Requirements ...	296	229
i. When Knowledge is “Direct”	296	—
ii. The Level of Direct Knowledge Relators Must Possess	298	229
c. When Knowledge Is “Independent”	301	—
d. The “Voluntary” Requirement	302	—
D. Developing Evidence That Supports Application of the Public Disclosure Jurisdictional Bar	303	—
 Chapter 4. Practical Considerations for Defending Health Care Fraud and Abuse Cases	 321	 231
I. The Evolving Nature of Health Care Fraud and Abuse Enforcement	323	232
A. The Early Days	323	—
B. Medicare and Medicaid	324	—
C. The Late 1970s and 1980s	325	—
D. Deregulation	326	—
E. Office of Inspector General	327	232
F. The <i>Hanlester</i> Case	328	232
II. Sources of Health Care Fraud and Abuse Investigations	329	233
A. Internal Sources	330	—
B. External Sources	331	233
C. Importance of Determining the Source of Disclosed Information	332	—
III. Enforcement and Investigative Agencies	332	233
A. Federal Enforcement Agencies	333	233
B. State Enforcement and Investigative Agencies	334	234
C. Private Enforcers	335	—
IV. Enforcement Weapons	336	234
A. Federal Criminal Laws	336	234
1. General Criminal Laws	336	—
2. Health Care–Specific Criminal Statutes	336	234
a. Patient Protection and Affordable Care Act of 2010 (PPACA) and the Federal Anti-Kickback Statute [New Topic]	—	234
3. Health Insurance Portability and Accountability Act of 1996 (HIPAA)	336	234

a. Health Information Technology and Clinical Health Act (HITECH) [New Topic]	—	234
B. State Criminal Laws	337	—
C. Federal Civil Laws	338	235
1. Patient Protection and Affordable Care Act of 2010 (PPACA) [New Topic]	—	235
a. Anti-Kickback Violations and the FCA [New Topic]	—	236
b. Report and Return Requirement [New Topic]	—	236
c. Payment Suspension [New Topic]	—	236
d. Coordination of Integrity Efforts [New Topic]	—	236
D. State Civil Remedies	339	237
E. Federal Administrative Agency Remedies	339	—
1. Limited Judicial Review	340	—
2. Suspension of Payments	341	—
F. State Administrative Agency Remedies	342	—
G. Identifying the Remedy Threatened by the Enforcement Agency	343	—
V. Health Care Principles Being Enforced	344	—
A. Hierarchy	344	—
B. Importance of Reviewing All the Rules	344	—
1. Informal Guidelines	345	—
2. Agency Adjudicative Decisions	346	—
3. Other Pronouncements	347	—
C. Impact of the Rules	347	—
D. Private Party Interpretations, Practices, and Codes of Conduct	348	—
VI. Government Investigatory Strategies	349	—
A. Overview	349	—
B. Enforcement Agency Interviews	350	—
C. Document Production	352	—
VII. Responding to an Investigation	353	—
A. Understanding the Government's Interests	353	—
B. Communicating with Enforcement Agents and Their Attorneys	354	—
C. Explaining the Client's Position	355	—
D. Position Papers	355	—
E. The Context Concept	356	—
F. Explaining Industry Terms and Practices	358	—
VIII. Impact of Investigations	359	237
A. Timing	359	—
B. Publicity	360	—
C. Effect on Business	360	—
D. Cash Flow Consequences	361	—
E. Suing Government Officials for Reckless Investigations and Related Actions	361	237
IX. Settlement Considerations	362	—
A. Collateral Consequences	362	—
B. Binding the Government	363	—
C. Settlement Goals	364	—
D. Life After a Settlement	364	—
X. Litigation Defense Strategies	365	—
A. Importance of the Fundamentals	365	—
1. Necessity of Prohibited Act or Omission	366	—

2.	Necessity of Wrongful Intent	366	—
3.	Necessity of Agency Authority to Act	369	—
B.	Other Practical Defense Concepts	369	—
1.	Stressing the Facts	369	—
2.	Burden of Proof Requirements	370	—
3.	Credibility of Defendant	371	—
4.	Limited Judicial Review	371	—
XI.	Current Enforcement Priorities	372	238
A.	Focus Areas for OIG Investigation and Enforcement	372	—
B.	Noteworthy Settlements Since 2005 [Amended Topic] ..	376	238
XII.	Enforcement Actions Involving Pharmaceuticals	378	242
A.	Introduction	378	—
B.	Enforcement Actions Involving Pricing Methodologies	379	242
1.	Price Inflation Through Average Wholesale Price Data	379	242
2.	Medicaid Drug Rebate Program	382	242
C.	Illegal Marketing	383	243
1.	Kickbacks	383	—
2.	Drug Switching	386	—
3.	Marketing of Off-Label Uses	388	243
4.	Free Samples	390	—
D.	Defense Strategies	390	—
1.	Federal False Claims Act	390	—
a.	Government Knowledge of Pricing Scheme	391	—
b.	Challenging Scienter	392	—
c.	Challenging Causation	394	—
2.	Anti-Kickback Statute	395	—
a.	Kickbacks as False Claims: Lack of Certification	395	—
b.	Statutory Exception and Safe Harbor Protection: Discounts and Educational Grants	396	—
E.	Class Action Lawsuits on Behalf of Private Payors and Patients	396	—
F.	Counterfeit Drugs, Illegal Wholesaling, and Internet Pharmacies	397	—
G.	New Laws Empowering Enforcement Agencies	397	—
H.	Conclusion	400	—
XIII.	The Intersection of the Stark Law and the False Claims Act	401	246
A.	Introduction	401	—
B.	Basis for Liability	401	—
C.	Recent Litigation Involving the Stark Law and the FCA	402	246
D.	Defense Strategies	403	246
E.	Conclusion	405	—
XI	Emerging Issues: Sarbanes-Oxley and the New Era		
V.	of Corporate Responsibility	405	—
A.	Relevant Provisions of the Sarbanes-Oxley Act	405	—
B.	Recent Litigation	406	—
XV.	Conclusion	407	—

Chapter 5. Legal Issues Surrounding Hospital and Physician Relationships [Substitute Text]	—	247
I. Background on the Nature of Relationships Between Hospitals and Physicians and the Factors Affecting Those Relationships	—	249
II. Legal Issues	—	251
III. Relationships With Physicians Who Are Members of the Voluntary Medical Staff	—	255
A. Medical Staff Membership	—	255
1. Exclusive Contracts	—	256
2. Economic Credentialing	—	256
a. Anti-Kickback Issues	—	258
b. State Issues	—	259
B. Credential Review and Corrective Action	—	260
1. Verification of Credentials and Checking Available Databases	—	260
2. Physician Malpractice Insurance	—	261
3. Hospital Duty to Deal With Problem Practitioners ...	—	261
C. Corrective Action Under the Medical Staff Bylaws	—	265
D. Physician Attestation of Accuracy of Medicare Diagnoses	—	266
E. Physician Coverage of the Emergency Room	—	267
1. Reimbursement	—	268
2. Corporate Practice of Medicine Prohibitions	—	269
F. Perquisites for Members of the Medical Staff	—	270
1. Nonmonetary Compensation	—	270
2. Medical Staff Incidental Benefits	—	271
3. Professional Courtesy	—	272
4. Compliance Training	—	274
G. Donations of Health Information Technology	—	274
1. Community-Wide Health Information Systems Exception	—	274
2. Electronic Prescribing Exception	—	276
3. Electronic Health Records Exception	—	277
4. HITECH Act	—	279
H. Medicare Prohibition on Unbundling	—	279
I. Physician Use of Hospital Clinic Space	—	280
IV. Contractual Relationships With Physicians	—	282
A. Generally Applicable Limitations Arising From Tax-Exempt Status Can Be the Basis for Intermediate Sanctions Under the Internal Revenue Code	—	282
1. Definition of “Disqualified Persons”	—	283
2. Definition of “Reasonable Compensation”	—	285
3. Rebuttable Presumption That a Transaction Is Not an Excess Benefit	—	285
4. Rules for Revenue-Sharing Transactions	—	285
5. Hospital Project Final Report	—	286
B. Lease of Space	—	287
1. Clarification of “Fair Rental Value”	—	290
C. Lease of Equipment	—	291
D. Medical Director Agreements	—	293
E. Employing and Contracting With Physicians for the Provision of Patient Care Services	—	296

1. Federal Compliance Issues	—	296
2. State Corporate Practice of Medicine Prohibitions	—	299
3. Medicare and Medicaid Prohibitions on the Reassignment of Revenue	—	300
F. Hospital-Based Physicians	—	302
1. Exclusivity	—	302
2. Anti-Kickback and Stark Issues	—	303
3. False Claims Issues	—	303
G. Discounts on Reference Laboratory Services	—	305
H. Practice Management Services Furnished by Hospitals to Physicians	—	306
I. Academic Medical Centers	—	307
1. Stark Issues	—	308
2. Anti-Kickback Issues	—	310
J. Gainsharing	—	311
1. Civil Monetary Penalties for Improper Incentive Plans	—	312
2. Gainsharing Within Managed Care	—	319
3. Stark Issues	—	320
4. Anti-Kickback Issues	—	321
5. Tax-Exempt Issues	—	324
K. Physician Recruitment	—	326
1. Tax-Exempt Issues	—	327
2. Anti-Kickback Issues	—	329
3. Stark Issues	—	334
L. Physician Retention	—	337
1. Stark Issues	—	337
2. Provision of Malpractice Insurance Assistance	—	338
V. Joint Ventures Between Hospitals and Physicians	—	341
A. Whole Hospital Ventures	—	341
1. Stark Issues	—	342
2. Anti-Kickback Issues	—	344
3. Tax-Exempt Issues	—	346
B. Ambulatory Surgery Centers	—	349
1. Stark Issues	—	350
2. Federal Anti-Kickback Issues	—	350
C. Under-Arrangements	—	355
1. Provider Based Requirements	—	355
2. Anti-Kickback Issues	—	356
3. Stark Issues	—	357
D. Physician-Hospital Organizations	—	358
1. Capital Requirements and the Need to Avoid Hospital Subsidization of Physician Members	—	358
2. Antitrust Issues	—	359
3. Business of Insurance	—	361
E. Service Line Leases	—	361
1. Stark Issues	—	362
2. Anti-Kickback Issues	—	362
3. Anti-Markup Issues	—	364
F. Acquisitions of Physician Practices	—	365
G. Clinical Co-Management	—	367
H. Accountable Care Organization	—	368

Chapter 6. Managed Care Fraud and Abuse: Risk Areas for Government Program Participants	489	371
I. Introduction	490	—
A. Managed Care Fraud and Abuse Enforcement as Outgrowth of Fee-for-Service Model	490	—
B. Medicare Modernization Act	491	—
II. Compliance Programs in Managed Care Organizations	492	372
A. Medicare Advantage Organizations	493	372
1. The OIG Guidance	494	—
a. Standards, Policies, and Procedures	494	—
i. Marketing Materials and Personnel	495	—
ii. Selective Marketing and Enrollment	496	—
iii. Disenrollment	497	—
iv. Underutilization and Quality of Care	497	—
v. Data Collection and Submission Processes	497	—
vi. Anti-Kickback Statute and Other Inducements	498	—
vii. Emergency Services	499	—
b. Record Retention	499	—
c. Compliance as Part of Employee Evaluation	500	—
d. Subcontractor Compliance	500	—
e. Compliance Officer	500	—
f. The Compliance Committee	501	—
g. Compliance Training	501	—
h. Effective Lines of Communication	502	—
i. Auditing and Monitoring	502	—
j. Discipline	502	—
k. Corrective Action	502	—
B. Medicare Part D	503	372
C. The Deficit Reduction Act	509	—
III. Areas of Government Review, Monitoring, and Audit	510	373
A. Centers for Medicare and Medicaid Services	510	373
1. Audits	510	—
2. Marketing	512	373
3. Risk Adjustment Validation [New Topic]	—	377
B. The OIG Work Plans	513	379
1. Medicare Advantage	514	379
2. Medicare Part D	515	380
3. Medicaid Managed Care [New Topic]	—	381
IV. Enforcement Actions	518	381
A. Medicare	518	381
B. Medicaid	518	382
C. Federal Employees Health Benefits Program	519	—
1. Overview	519	—
2. Enforcement Actions Against Managed Care Organizations in the Federal Employees Health Benefits Program	519	—
V. Potential False Claims Act and False Statement Liability Under Medicare Advantage, Medicare Part D, and Other Government Health Programs [Amended Topic]	520	383
A. Culpable Parties	521	—
B. Levels of Knowledge	521	—

C. Definition of “Claim” [Substitute Text]	—	384
D. Damages	522	—
E. Liability for Submission of Certified Rate, Enrollment, and Encounter Data	524	—
1. Medicare Advantage Bid Submission	524	—
2. Part D	525	—
F. Medicare Secondary Payor Provisions	526	—
G. Reporting of Commissions and Fees Paid to Insurance Brokers and Agents	527	—
H. PBM Fraud and Abuse Issues	527	385
I. Other Statutes	529	—
VI. Managed Care Exceptions to the Anti-Kickback Statute	530	—
A. Negotiated Rulemaking	530	—
B. Capitated Managed Care Entity Safe Harbor	531	—
C. Risk-Sharing Safe Harbor	531	—
D. Some Common Elements of Both Safe Harbors	532	—
1. Health Care Items and Services	533	—
2. No Swapping or Shifting of Financial Burden	533	—
VII. Prompt Payment and Denial of Care Compliance Issues	534	386
A. Prompt Payment	534	386
B. Denial of Care	535	—
VIII. Increased State Enforcement Efforts	536	—
IX. Conclusion and Practical Pointers	537	—
Chapter 7. Corporate Compliance Programs	539	387
I. Introduction	542	388
A. Compliance Program Requirements Under PPACA [New Topic]	—	388
II. Benefits of a Corporate Compliance Program	544	390
A. Federal Sentencing Guidelines	544	390
1. Probation	545	—
2. Reduced Fines	546	—
3. Elements of an “Effective” Compliance Program	548	—
4. Implication of the Supreme Court’s Booker Decision on Corporate Compliance Programs	550	—
B. HHS Guidelines on Permissive Exclusion	552	—
III. Elements of an Effective Compliance Program	553	391
A. Corporate Integrity Agreements and Deferred Prosecution Agreements [Amended Topic]	555	391
B. Model Corporate Compliance Programs	555	392
1. Compliance Program Guidance for Hospitals	556	—
a. Hospital Risk Areas	561	—
i. Submission of Accurate Claims and Information	561	—
(a) Outpatient Procedure Coding	561	—
(b) Admissions and Discharges	562	—
(c) Supplemental Payment Considerations	562	—
(d) Use of Information Technology	563	—
ii. The Physician Self-Referral Law (Stark Law) and Federal Anti-Kickback Statute	563	—
(a) Stark Law Compliance	563	—

(b) Anti-Kickback Compliance	564	—
iii. Gainsharing Arrangements	566	—
iv. EMTALA	567	—
v. Substandard Care	567	—
vi. Relationships With Federal Health Care Beneficiaries	567	—
vii. HIPAA Privacy and Security Rules	568	—
viii. Topics of General Interest to Hospitals	568	—
b. Ensuring Compliance Program Effectiveness	569	—
i. Developing a General Code of Conduct	569	—
ii. Regularly Reviewing Compliance Program Elements	569	—
(a) Designating a Compliance Officer and Compliance Committee	569	—
(b) Developing Compliance Policies and Procedures	570	—
(c) Developing Open Lines of Communication	571	—
(d) Appropriate Training and Education	571	—
(e) Internal Monitoring and Auditing	572	—
(f) Responding to Detected Deficiencies	572	—
(g) Enforcing Disciplinary Standards	573	—
2. Compliance Program Guidance for Clinical Laboratories	573	—
a. Clinical Laboratory Risk Areas	574	—
i. Medical Necessity	574	—
(a) Requisition Form	574	—
(b) Notices	574	—
(c) Physician Acknowledgements	574	—
(d) Advanced Beneficiary Notices	575	—
(e) Test Utilization Monitoring	575	—
ii. Billing	575	—
(a) Selecting CPT or HCPCS Codes	575	—
(b) Selecting ICD-9-CM Codes	575	—
(c) Tests Covered by Claims for Reimbursement	575	—
(d) Calculations	576	—
(e) Reflex Testing	576	—
(f) Reliance on Standing Orders	576	—
iii. Marketing	576	—
iv. Prices Charged to Physicians	576	—
b. Ensuring Compliance Program Effectiveness	576	—
i. Dealing with Employees and Contractors	577	—
ii. Audits	577	—
iii. Investigations	578	—
3. Compliance Program Guidance for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Providers	578	—
a. DME Risk Areas	579	—
B. Ensuring Compliance Program Effectiveness	580	—
i. Compliance Officer Responsibilities	580	—
ii. Education and Training	581	—
(a) Claim Development and Billing Training	581	—

(b) Sales and Marketing Training	581	—
(c) Ongoing Education Responsibilities ...	581	—
iii. Hotline	582	—
iv. Auditing and Monitoring	582	—
v. Corrective Action	582	—
4. Compliance Program Guidance for Third-Party Medical Billing Companies	583	—
a. Billing Company Risk Areas	583	—
b. Reporting Provider Misconduct	584	—
5. Compliance Program Guidance for Hospices	585	—
a. Hospice Risk Areas	585	—
6. Compliance Program Guidance for Nursing Facilities	586	392
a. Nursing Facility Risk Areas	586	—
i. Quality of Care	586	—
ii. Residents' Rights	587	—
iii. Billing and Cost Reporting	587	—
iv. Employee Screening	588	—
v. Kickbacks, Inducements, and Self- Referrals	588	—
b. Ensuring Compliance Program Effectiveness	589	—
i. Auditing and Monitoring	589	—
ii. Disciplinary Guidelines	589	—
iii. Corrective Action	589	—
c. OIG Supplemental Compliance Program Guidance for Nursing Facilities [New Topic]	—	392
i. Quality of Care Risk Areas [New Topic] ...	—	393
(a) Sufficient Staffing [New Topic]	—	393
(b) Comprehensive Resident Care Plans [New Topic]	—	393
(c) Appropriate Use of Psychotropic Medications [New Topic]	—	394
(d) Medication Management [New Topic]	—	394
(e) Resident Safety [New Topic]	—	395
ii. Submission of Accurate Claims Risk Areas [New Topic]	—	396
(a) Proper Reporting of Resident Case- Mix [New Topic]	—	396
(b) Therapy Services [New Topic]	—	396
(c) Screening for Excluded Individuals and Entities [New Topic]	—	397
(d) Restorative and Personal Care Services [New Topic]	—	397
iii. The Federal Anti-Kickback Statute [New Topic]	—	397
(a) Free Goods and Services [New Topic]	—	398
(b) Services Contracts [New Topic]	—	399
(c) Discounts [New Topic]	—	400
(d) Hospices [New Topic]	—	401
(e) Reserved Bed Arrangements [New Topic]	—	401
iv. Other Risk Areas [New Topic]	—	401

(a) Physician Self-Referrals [New Topic]	—	401
(b) Anti-Supplementation [New Topic] ...	—	402
(c) Medicare Part D [New Topic]	—	402
(d) HIPAA Privacy and Security Rules [New Topic]	—	403
v. An Ethical Culture [New Topic]	—	403
(a) Code of Conduct [New Topic]	—	403
(b) Regular Review of Compliance Program Effectiveness [New Topic] ...	—	403
(c) Communication to Decisionmakers [New Topic]	—	403
vi. Self-Reporting [New Topic]	—	404
7. Compliance Program Guidance for Medicare+Choice Organizations	590	404
a. Risk Areas	590	—
8. Compliance Program Guidance for Individual and Small-Group Physician Practices	591	—
b. Ensuring Compliance Program Effectiveness	576	—
a. Risk Areas for Physicians	592	—
b. Other Helpful Resources for All Health Care Organizations	593	—
9. Compliance Program Guidance for Home Health Agencies	594	—
a. Home Health Agency Risk Areas	594	—
i. Improper Joint Ventures	594	—
ii. Billing for Unallowable Costs of Home Health Coordination	594	—
iii. Unqualified or Unlicensed Personnel	595	—
iv. Falsified Plans of Care	595	—
v. Improper Patient Solicitation Activities and High-Pressure Marketing	595	—
vi. Billing for Services to Patients Who Are Not Truly Homebound	595	—
vii. Billing for Visits to Patients Who Do Not Require a Qualifying Service	595	—
viii. Duplication of Services	596	—
ix. Willing Caregivers	596	—
10. Compliance Program Guidance for Ambulance Suppliers	596	—
a. Ambulance Risk Areas	596	—
i. Medical Necessity and Upcoding	596	—
ii. Documentation, Billing, and Reporting	597	—
iii. Medicare Part A Payment for Services “Under Arrangements”	597	—
iv. Medicaid Requirements	597	—
v. Arrangements With Patients and Other Providers	597	—
vi. Additional Risk Areas	597	—
b. Making a Compliance Program Effective	598	—
i. Auditing and Monitoring	598	—
11. Compliance Program Guidance for Pharmaceutical Manufacturers	598	404
a. Compliance Program Elements	599	—

b.	Risk Areas for Drug (and Device) Companies	600	—
i.	Integrity of Data Used to Establish Reimbursement	600	—
ii.	Kickback and Other Illegal Remuneration	601	—
iii.	Risks Related to Purchasers	601	—
(a)	Discounts and Remuneration to Purchasers	601	—
(b)	Formularies and Formulary Support Services	603	—
(c)	Average Wholesale Price	604	—
iv.	Relationships With Physicians and Other Referral Sources	604	—
v.	Relationships With Sales Agents	607	—
vi.	Drug Samples	607	—
12.	Draft Compliance Program Guidance for NIH Grant Recipients	608	—
a.	High Risk Areas for NIH Grant Recipients	608	—
i.	Time and Effort Reporting	608	—
ii.	Proper Allocation of Charges	609	—
iii.	Reporting Financial Support from Other Sources	609	—
13.	Part D Program to Control Fraud, Waste, and Abuse	609	405
a.	Description of Compliance Program Elements	610	405
b.	Medicare Drug Integrity Contractors (MEDICs)	612	—
c.	Part D Sponsor Accountability and Oversight	613	—
d.	Risk Factors for Part D Plans	613	—
i.	Part D Plan Sponsors	614	—
ii.	PBMs	614	—
iii.	Pharmacies	615	—
iv.	Prescribers	615	—
v.	Wholesalers	615	—
vi.	Manufacturers	616	—
vii.	Medicare Beneficiaries	616	—
IV.	Practical Issues in Developing and Implementing		
a.	Compliance Program	617	406
A.	Selecting a Compliance Officer	617	—
B.	Developing a Corporate Compliance Program	618	—
C.	Education and Training	619	—
D.	Budgeting	620	—
E.	Compliance Hotline	620	—
F.	Compliance Helpline	621	—
G.	Auditing and Monitoring	621	406
1.	Attorney-Client Privilege	622	—
2.	External/Expert Reviews	623	—
3.	Expert Findings	623	—
4.	Types of Reviews	623	—
5.	Disclosure Obligations and Repayments	624	406
H.	Recent Compliance Developments at the State Level	625	407
V.	Conclusion	626	—

Chapter 8. Potential Liabilities for Directors and Officers of Health Care Organizations	629	409
I. Introduction	630	409
II. Responsibilities of Directors and Officers	634	412
A. Criminal Liability	634	412
1. General Rule	634	412
2. Responsible Corporate Officer Doctrine	642	413
B. Civil Liability	643	414
1. Fiduciary Responsibilities and Duties	643	414
a. Duty of Loyalty	644	—
i. Good Faith	645	—
ii. Fairness (No Conflicts)	646	—
iii. Usurping Corporate Opportunity	647	—
b. Duty of Care	647	—
c. Duty of Candor	647	—
d. Duties of Nondirector Officers	648	414
e. Other Types of Exposure	649	415
2. Limitations on the Liability of Directors and Officers	649	415
a. Business Judgment Rule	649	—
b. Statutory and Corporate Measures to Reduce Directors' and Officers' Liability	652	415
c. Indemnification and Insurance	652	—
C. The Sarbanes-Oxley Act and Related Developments	654	—
D. Health Care Reform [New Topic]	—	416
III. Litigation Against Officers and Directors	658	—
A. Shareholder Derivative Actions	658	—
1. Shareholder Derivative Actions in General	658	—
2. Presuit Demand Requirements	659	—
3. Other Requirements for Derivative Actions	661	—
B. Class Actions	661	—
1. Class Action Requirements	662	—
2. Class Not Limited to Shareholders	663	—
3. The Private Securities Litigation Reform Act and the Securities Litigation Uniform Standards Act	664	—
C. The Caremark Decision	666	—
1. Background of the Case	666	—
2. The Court's Decision	668	—
a. Board's Duty of Care Responsibilities	668	—
b. Appropriate Information Gathering and Reporting Systems	670	—
D. The Columbia/HCA Litigation	672	—
1. Columbia/HCA Operations and Government Investigations	672	—
2. Shareholders' Allegations in <i>McCall v. Scott</i>	674	—
3. Defendants' Response	677	—
4. The Magistrate's Report and District Court Decision	677	—
a. The Test Under Delaware Law	678	—
b. Applying the Test to the Facts in <i>McCall</i>	679	—
i. Improper Actions by Defendants	679	—
ii. The "Red Flag" Theory	680	—

5.	The Appellate Court Decisions	682	—
a.	The Legal Standards Used	682	—
b.	Analysis of the Facts	685	—
c.	<i>McCall</i> and the <i>Abbott Laboratories</i> Case	687	—
6.	Implications of the Columbia/HCA and <i>Abbott Laboratories</i> Decisions	691	—
a.	The Sixth Circuit Decision in <i>McCall</i>	691	—
b.	Other Developments Relating to Presuit Demand	693	—
E.	<i>Stone v. Ritter</i> —Upholding the <i>Caremark</i> Standard for Director Liability	695	—
F.	<i>Spitzer v. Abdelhak</i>	695	—
1.	Background of the Case	695	—
2.	The Court’s Decision	697	—
IV.	Corporate Compliance	699	422
A.	U.S. Sentencing Guidelines	699	422
1.	Advantages of Compliance Programs	700	—
2.	Compliance Programs Must Be “Effective”	701	422
3.	Concerns Raised by Compliance Programs	707	—
B.	The Office of Inspector General Compliance Program Guidance	708	423
1.	Seven Basic Elements	709	—
2.	Specific References to <i>Caremark</i>	710	—
3.	Director and Officer Responsibilities for Compliance	710	—
a.	Establishing a Compliance Program	710	—
b.	Continuing Compliance Responsibilities	711	—
C.	Additional Guidance for Directors [New Topic]	—	424
V.	Recommendations to Reduce Exposure	712	—

**Chapter 9. The Disclosure Dilemma:
How, When, and What to Tell Stockholders and
Stakeholders About Your *Qui Tam* Suit
or Investigation**

		719	425
I.	Introduction	721	—
A.	A Brief Vignette	721	—
B.	The Problem	722	—
II.	Sources of Disclosure Obligations Under the Federal Securities Laws	724	425
A.	Publicly Traded Issuers	724	425
1.	The 1934 Act	726	425
a.	The 10-K and General Principles of 1934 Act Disclosure	726	425
b.	Quarterly Reports on Form 10-Q	733	426
c.	Current Reports on Form 8-K	734	—
2.	The 1933 Act	735	—
3.	Informal Disclosures: Analysts, Investor Relations, the Press, and Regulation FD	736	—
4.	The Elusive Concept of “Materiality”	739	—
a.	Common Law and Lore	739	—
b.	SAB 99	741	—
B.	Tax-Exempt Issuers	743	—
1.	Concerns Under the Federal Securities Laws	743	—

2.	Concerns Under Circular 230 and the Weiss Decision	745	—
C.	Disclosure as a Matter of Prudence	747	426
III.	The Problem, Restated and Amplified	747	—
A.	The Nature of Health Care Investigations and Prosecutions in General	748	—
1.	Complexity of the Regulatory Environment	748	—
2.	The Wide Range of Remedial Statutes	748	—
3.	The Overarching Impact of the False Claims Act	750	—
4.	The Curious Nature of Prosecutorial Discretion in Health Care Cases	752	—
B.	Special Problems for Tax-Exempt Providers	757	—
C.	The Problem Summarized	759	—
IV.	An Approach to Analyzing and Responding to Disclosure Issues in the Health Care Setting	761	—
A.	Determining When to Disclose	763	—
1.	What Does the Issuer Know About the Existence and Procedural Context of the Investigation or Proceeding (and How Did It Come By That Knowledge)?	763	—
2.	What Does the Issuer Know About the Materiality of the Investigation or Proceeding?	766	—
a.	What Is the Nature of the Claims at Issue?	766	—
b.	Does the Issuer Have Good Defenses (and Will That Be Apparent to the Government at an Early Stage)?	767	—
c.	What Is the Potential Financial Exposure?	767	—
d.	Is the Proceeding Civil or Criminal	769	—
e.	Is the Proceeding a Qui Tam Suit at the Pre-Intervention Stage?	770	—
f.	Is the Issuer Pursuing a Settlement Strategy or Litigating Aggressively?	770	—
g.	What Is the Likely Market Reaction?	771	—
3.	Does the Issuer Have a Duty of Disclosure?	772	—
a.	Is There a Specific Requirement of Disclosure Under the 1933 Act or the 1934 Act?	772	—
b.	Is Disclosure Necessary to Ensure That Other Statements by the Issuer Are Not Misleading?	773	—
c.	What About Rumors?	774	—
B.	Determining How and What to Disclose	775	—
1.	How Does the Issuer Deal with a False Claims Act Seal?	775	—
2.	By What Means Should the Issuer Make Disclosure?	776	—
3.	What Should the Disclosure Actually Say?	779	—
C.	Protecting the Disclosure Decision	781	—
V.	Brief Thoughts on Investigation-Related Disclosure Issues in Other Contexts	783	—
A.	Venture Capital/Private Equity Transactions	783	—
B.	Loan Agreements	784	—
C.	Merger and Acquisition Transactions	786	—
D.	Research Grant Activities	788	—
E.	Private Philanthropy	789	—
VI.	A Sidebar: What if the Attorney and the Issuer Disagree?	789	428

VII. Conclusion: Now We See as Through a Glass, Darkly (but Later, the Plaintiff Will Clear Things Up for Us	792	—
Chapter 10. Controlling Fraud, Waste, and Abuse in the Medicare Part D Program	795	435
I. Introduction	797	436
A. Overview [Substitute Text]	—	436
B. Anatomy of the Part D Benefit and the Potential for FWA [Substitute Text]	—	437
C. Part D Oversight and Enforcement [New Topic]	—	441
1. Early Preparation [New Topic]	—	441
2. Changes Under the Medicare Improvements for Patients and Providers Act and Subsequent Regulations [New Topic]	—	447
D. CMS Oversight of Part D Program Compliance [New Topic]	—	450
E. Sponsor Oversight of Subcontractors [New Topic]	—	453
II. The OIG’s Part D Agenda	805	455
A. OIG Work Plans [Substitute Text]	—	455
1. Work Plan—Study Results	—	456
a. Implementation of Required Programs to Deter Fraud, Waste, and Abuse	—	456
b. Bid Submission by Part D Sponsors	—	457
c. Disenrollment of Deceased Beneficiaries	—	458
d. Reconciliation Payments for 2006 and 2007	—	458
e. Medicare Drug Integrity Contractors’ Detection of Fraud and Abuse	—	458
f. E-Prescribing in Part D	—	459
g. Medicare Prescription Drug Plans Formulary Changes	—	459
2. 2010 Work Plan	—	459
a. Planned Studies and Audits Related to the Accuracy of Data Submitted by Sponsors to CMS	—	460
i. Medicare Part D Data Submitted by Sponsors for Reconciliations	—	460
ii. Bid Submissions by Part D Sponsors	—	460
iii. Administrative Costs Included in Bid Submissions	—	460
iv. Part D Pharmaceutical Manufacturer Rebates	—	460
b. Planned Studies and Audits Addressing Oversight of the Part D Program by CMS and Sponsors	—	461
i. Part D Sponsors’ Audits of Pharmacies	—	461
ii. Medicare Part D Program Audit Overview	—	461
iii. Medicare Part D Sponsors’ Internal Controls for Fraud, Waste and Abuse	—	461
c. Planned Studies and Audits Regarding Potentially Erroneous Payments for Inappropriate Claims	—	461

Detailed Table of Contents

xlix

i.	Duplicate Drug Claims for Hospice Beneficiaries	—	461
ii.	Duplicate Medicare Part A and Part B Claims Included With Part D Claims	—	461
iii.	Part D Drug Claims With Inactive or Invalid Physician Identifier Numbers	—	462
iv.	Medicare Part D Payments for Drugs Prescribed or Provided by Excluded Providers	—	462
d.	Part D Sponsors' Audits of Pharmacies	—	—
e.	E-Prescribing in Part D	—	—
f.	Oversight of Pharmacy Benefit Managers	—	—
g.	Impact of Rebates on Long-Term Care Pharmacies	—	—
h.	Medicare Prescription Drug Plans Formulary Changes	—	—
B.	Patient Assistance Programs	828	462
III.	Part D Regulatory Requirements With Significant FWA Compliance Implications	835	—
A.	Data Reporting Requirements	835	—
B.	Marketing Guidelines	839	—
C.	Drug Formulary Requirements	847	—
D.	FWA Compliance Program Requirements and Guidelines	852	—
1.	Overview of Fraud, Waste, and Abuse	855	—
2.	Sponsor Accountability and Oversight	855	—
3.	The Basics of a Program to Control Fraud, Waste, and Abuse	856	—
4.	Components of a Comprehensive Program to Detect, Prevent, and Control Part D Fraud, Waste, and Abuse as Part of the General Compliance Plan Requirements	857	—
a.	Written Policies and Procedures	857	—
b.	Compliance Officer and Committee	857	—
c.	Training and Education	858	—
d.	Effective Lines of Communication	858	—
e.	Enforcement of Standards	858	—
f.	Monitoring and Auditing	859	—
g.	Conducting a Timely and Reasonable Inquiry of Detected Offenses	859	—
h.	Corrective Actions	860	—
5.	Implementing a Comprehensive Program to Detect, Correct, and Prevent Fraud, Waste, and Abuse and Procedures to Voluntarily Self-Report Potential Fraud and Misconduct	860	—
a.	Risk Areas for Part D Plan Sponsors	860	—
b.	Risk Areas for Pharmacy Benefit Managers	862	—
c.	Risk Areas for Pharmacies	862	—
d.	Risk Areas for Prescribers	863	—
e.	Risk Areas for Wholesalers	863	—
f.	Risk Areas for Pharmaceutical Manufacturers	864	—
g.	Risk Areas for Medicare Beneficiaries	864	—
h.	Additional Vulnerabilities	865	—
IV.	Reporting Part D FWA	866	—

V. Recent Developments in Part D Compliance		
[New Topic]	—	463
A. Sponsors' Marketing Practices a Continual Source of Concern for FWA [New Topic]	—	463
B. Enforcement Actions [New Topic]	—	468
C. Proposed Rule Heightens Compliance Program Requirements and Alters Corrective Action Plan Process [New Topic]	—	470
D. OIG Review of SilverScript Internal Controls to Guard against Fraud, Waste, and Abuse for the Medicare Part D Program [New Topic]	—	472
E. Patient Protection and Affordable Care Act [New Topic]	—	474
1. New and Enhanced Programs for Fighting FWA in the Medicare Part D Program [New Topic]	—	474
2. New Penalties Related to Medicare Part D FWA [New Topic]	—	475
3. Reporting and Return of Overpayments [New Topic]	—	476
4. Medicare Coverage Gap Discount Program [New Topic]	—	477
Chapter 11. Fraud and Abuse Issues Surrounding Clinical Trials [New Chapter]	—	479
I. Introduction	—	480
II. Financial Misconduct in Clinical Research	—	481
A. Payment for Clinical Research	—	481
1. Background and General Description	—	481
a. Medicare Coverage for Clinical Trials and Related Costs	—	481
i. National Coverage Decision	—	481
ii. Device Trials	—	483
b. General Parameters for Billing Third-Party Payors for Experimental Treatment	—	484
c. Payments for Treatment of Research-Related Injuries: Medicare Secondary Payer Rule	—	484
2. Fraud and Abuse Risks Associated with Payment for Clinical Trials and Related Costs	—	486
a. False Claims Act Violations	—	486
b. Beneficiary Anti-Kickback Statute Violations	—	487
c. Stark Law Violations	—	490
d. Beneficiary Anti-Inducement Statute Violations	—	491
e. Exclusion	—	492
f. Foreign Corrupt Practices Act Violations	—	492
3. Recommendations for Compliance	—	494
a. Pre-trial Budget Evaluation and Preparation	—	494
b. Research Billing Procedures	—	495
c. Audits	—	495
d. Development and Updating of Policies, Procedures, and Training	—	495
B. Federal Grants Management	—	495
1. Background and General Description	—	496

a.	Certifications	—	496
b.	Time-and-Effort Reporting and Salary Allocation	—	498
c.	Allowable Costs	—	499
d.	Cost Transfers	—	500
e.	Subrecipient Monitoring	—	501
2.	Fraud and Abuse Risks Associated With Mismanagement of Federal Grant Funds	—	502
a.	False Claims Act Violations	—	502
b.	Exclusion	—	503
3.	Recommendations for Compliance	—	504
III.	Misconduct in Protecting Human Subjects	—	505
A.	Overview of Human Subject Protection Regulations	—	506
1.	General Human Subject Protection	—	506
a.	Informed Consent Requirements	—	506
b.	IRB Requirements	—	507
2.	Conflicts of Interest	—	507
B.	Fraudulent Activities by Researchers	—	509
1.	Informed Consent	—	509
2.	Conflicts of Interest	—	510
3.	Misrepresentation to IRBs	—	510
4.	Misrepresentation to Regulatory Agencies	—	511
C.	Recommendations for Compliance	—	512
IV.	Research Misconduct	—	513
A.	Description of Research Misconduct and Associated Fraud and Abuse Risks	—	513
B.	Recommendations for Compliance	—	515
V.	Conclusion	—	515
Appendix Table of Contents			— 517
Appendix A: Anti-Kickback Statute Materials			(on disk)
A-1.	Anti-Kickback Statute (42 U.S.C. §1320a-7b(b))		(on disk)
A-2.	Anti-Kickback Safe Harbor Regulations (42 C.F.R. §1001.952)		(on disk)
A-3.	Safe Harbors for Certain Electronic Prescribing and Electronic Health Records Arrangements Under the Anti-Kickback Statute (<i>effective Oct. 10, 2006</i>), 71 Fed. Reg. 45,110 (Aug. 8, 2006)		(on disk)
Appendix B: Stark Self-Referral Law Materials			(on disk)
B-1.	Stark Self-Referral Law (42 U.S.C. §1395nn)		(on disk)
B-2.	Stark Phase II Final Regulations (<i>effective July 26, 2004</i>), 69 Fed.Reg. 16,054, 16,126–43 (Mar. 26, 2004), <i>codified at</i> 42 C.F.R. §§411.350–361		(on disk)
B-3.	Stark Phase II Final Regulations: Interim Final Rule with Comment Period; Correcting Amendment Pertaining to Advisory Opinion Process (<i>effective July 26, 2004</i>), 69 Fed. Reg. 57,226 (Sept. 24, 2004), <i>codified at</i> 42 C.F.R. §§411.370–389		(on disk)
B-4.	Stark Phase III Final Regulations (<i>effective Dec. 4, 2007</i>), 72 Fed. Reg. 51,012 (Sept. 5, 2007)		(on disk)
B-5.	Federal Self-Referral Regulations (combined) (<i>effective Dec. 4, 2007</i>)		(on disk)

- B-6. Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships; Exceptions for Certain Electronic Prescribing and Electronic Health Records Arrangements: Final Rule (*effective Oct. 10, 2006*), 71 Fed. Reg. 45,140 (Aug. 8, 2006) (on disk)
- B-7. Delay of the Date of Applicability for Certain Provisions of Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships (Stark Phase III) (*delaying effective date for certain arrangements until Dec. 4, 2008*), 72 Fed. Reg. 64,161 (Nov. 15, 2007) (on disk)
- B-8. Physicians’ Referrals to Health Care Entities With Which They Have Financial Relationships (Stark Phase III), Correction (*effective Dec. 4, 2007*), 72 Fed. Reg. 68,075 (Dec. 4, 2007) (on disk)
- B-9. Proposed Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Proposed Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Proposed Elimination of the E-Prescribing Exemption for Computer-Generated Facsimile Transmissions (*proposed rule*), 72 Fed. Reg. 38,122 (July 12, 2007) (on disk)
- B-10. Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions (*effective January 1, 2008, except for amendments to §409.17 and §409.23, effective July 1, 2008, and amendments to §423.160, effective January 1, 2009*), 72 Fed. Reg. 66,222 (Nov. 27, 2007) (on disk)
- B-11. Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates; Proposed Changes to Disclosure of Physician Ownership in Hospitals and Physician Self-Referral Rules; Proposed Collection of Information Regarding Financial Relationships Between Hospitals and Physicians (*proposed rule*), 73 Fed. Reg. 23,528 (Apr. 30, 2008) (on disk)
- B-12. Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates; Payments for Graduate Medical Education in Certain Emergency Situations; Changes to Disclosure of Physician Ownership in Hospitals and Physician Self-Referral Rules; Updates to the Long-Term Care Prospective Payment System; Updates to Certain IPPS-Excluded Hospitals; and Collection of Information Regarding Financial Relationships Between Hospitals (*final rules*), 73 Fed. Reg. 48,434 (Aug. 19, 2008) (on disk)
- B-13. Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2009; E-Prescribing Exemption for Computer-Generated Facsimile Transmissions; and Payment for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) (*final rule with comment period*), 73 Fed. Reg. 69,726 (Nov. 19, 2008) (on disk)
- B-14. CMS Voluntary Self-Reference Disclosure Protocol (Sept. 23, 2010) (on disk)

Appendix C: Civil False Claims Act Materials	(on disk)
C-1. Civil False Claims Act (31 U.S.C. §§3729–3733)	(on disk)
C-2. Holder Memorandum: Guidance on the Use of the False Claims Act in Civil Health Care Matters, U.S. Dep’t of Justice (June 3, 1998); review (Feb. 3, 1999)	(on disk)
C-3. Thompson Memorandum: Principles of Federal Prosecution of Business Organizations, U.S. Dep’t of Justice, Office of Att’y General (Jan. 20, 2003)	(on disk)
C-4. McNulty Memorandum: Principles of Federal Prosecution of Business Organizations, U.S. Dep’t of Justice (Dec. 12, 2006)	(on disk)
C-5. Fraud Enforcement and Recovery Act (FERA), Pub. L. No. 111-21, 123 Stat. 1617 (May 20, 2009)	(on disk)
C-6. False Claims Act, redlined to reflect amendments enacted in FERA	(on disk)
C-7. 155 Cong. Rec. S4531, S4539 (Apr. 22, 2009), Sen. Kyl Remarks on FERA	(on disk)
Appendix D: Civil Monetary Penalties and Exclusion Materials	(on disk)
D-1. Civil Monetary Penalties Statute (42 U.S.C. §1320a-7a)	(on disk)
D-2. Table of Office of Inspector General (HHS) Program Exclusion Authorities	(on disk)
D-3. Exclusion of Entities From Government Health Care Programs Statute (42 U.S.C. §1320a-7)	(on disk)
D-4. Civil Monetary Penalties Regulations (42 C.F.R. Part 1003)	(on disk)
D-5. Regulations on Exclusion of Entities From Participation in Government Health Care Programs (42 C.F.R. Sections 1001.101–.3005)	(on disk)
Appendix E: Selected Health Care Fraud Statutes Related to Private Payer Fraud	(on disk)
E-1. Health Care Benefit Program False Statements Statute (18 U.S.C. §1035)	(on disk)
E-2. Health Care Fraud Statute (18 U.S.C. §1347)	(on disk)
E-3. Federal Health Care Offense Definitions Statute (18 U.S.C. §24) ..	(on disk)
Appendix F: Special Fraud Alerts and Advisory Bulletins	(on disk)
F-1. Special Fraud Alert: Rental of Space in Physician Offices by Persons or Entities to Which Physicians Refer (Feb. 2000)	(on disk)
F-2. Special Fraud Alert: Physician Liability for Certifications in the Provision of Medical Equipment and Supplies and Home Health Services (Jan. 1999)	(on disk)
F-3. Special Fraud Alert: Fraud and Abuse in Nursing Home Arrangements With Hospices (Mar. 1998)	(on disk)
F-4. Special Fraud Alert: Fraud and Abuse in the Provision of Services in Nursing Facilities (May 1996)	(on disk)
F-5. Special Fraud Alert: Provision of Medical Supplies to Nursing Facilities (Aug. 1995)	(on disk)
F-6. Special Fraud Alert: Home Health Fraud (June 1995)	(on disk)
F-7. Special Fraud Alert: Arrangements for the Provision of Clinical Laboratory Services (Oct. 1994)	(on disk)
F-8. Special Fraud Alert: Prescription Drug Marketing Schemes (Aug. 1994)	(on disk)

F-9.	Special Fraud Alert: Hospital Incentives to Referring Physicians (May 1992)	(on disk)
F-10.	Special Fraud Alert: Routine Waiver of Copayments or Deductibles Under Medicare Part B (May 1991)	(on disk)
F-11.	Special Fraud Alert: Joint Venture Arrangements (Aug. 1989)	(on disk)
F-12.	Special Advisory Bulletin: Practices of Business Consultants (June 2001)	(on disk)
F-13.	Special Advisory Bulletin: The Patient Anti-Dumping Statute (Nov. 1999)	(on disk)
F-14.	Special Advisory Bulletin: The Effect of Exclusion From Participation in Federal Health Care Programs (Sept. 1999)	(on disk)
F-15.	Special Advisory Bulletin: Gainsharing Arrangements and CMPs for Hospital Payments to Physicians to Reduce or Limit Services to Beneficiaries (July 1999)	(on disk)
F-16.	Medicare Advisory Bulletin: Questionable Practices Affecting the Hospice Benefit (Oct. 1995)	(on disk)
F-17.	OIG Management Advisory Report: Financial Arrangements Between Hospitals and Hospital-Based Physicians (Jan. 1991)	(on disk)
F-18.	OIG Special Advisory Bulletin: Offering Gifts and Other Inducements to Beneficiaries (Aug. 2002)	(on disk)
F-19.	OIG Special Fraud Alert: Telemarketing by Durable Medical Equipment Suppliers (Mar. 2003)	(on disk)
F-19.1	Updated Special Fraud Alert: Telemarketing by Durable Medical Equipment Suppliers (Jan. 2010)	(on disk)
F-20.	OIG Special Advisory Bulletin: Contractual Joint Ventures (Apr. 2003)	(on disk)
F-21.	OIG Special Advisory Bulletin: Patient Assistance Programs for Medicare Part D Enrollees (Nov. 2005)	(on disk)
F-22.	OIG Alert: Clinical Trials and Liability Insurance (Including Self-Insurance), No-Fault Insurance, and Workers' Compensation (May 26, 2010)	(on disk)

Appendix G: Advisory Opinion Materials: Anti-Kickback Statute and Stark Self-Referral Law

G-1.	Anti-Kickback Advisory Opinion Regulations (42 C.F.R. Part 1008)	(on disk)
G-2.	Topical Index (Cumulative) and Summaries of OIG Anti-Kickback Advisory Opinions: Years 2001–Oct. 6, 2010	(on disk)
G-3.	Office of Inspector General Preliminary Checklist for Advisory Opinion Requests (Anti-Kickback Statute) (July 1999)	(on disk)
G-4.	Stark Law Advisory Opinion Regulations (42 C.F.R. Sections 411.370–389)	(on disk)
G-5.	Overview of Stark Law Advisory Opinion Process	(on disk)
G-5.1.	Stark Law Advisory Opinion No. HCFA-AO-98-001 (1998)	(on disk)
G-5.2.	Stark Law Advisory Opinion No. HCFA-AO-98-002 (1998)	(on disk)
G-5.3.	Stark Law Advisory Opinion No. CMS-AO-2005-08-01 (2005)	(on disk)
G-5.4.	Stark Law Advisory Opinion No. CMS-AO-2006-01 (2006)	(on disk)
G-5.5.	Stark Law Advisory Opinion No. CMS-AO-2007-01 (2007)	(on disk)
G-5.6.	Stark Law Advisory Opinion No. CMS-AO-2008-01 (May 2008)	(on disk)
G-5.7.	Stark Law Advisory Opinion No. CMS-AO-2008-02 (June 2008)	(on disk)

Appendix H: Office of Inspector General Self-Disclosure Protocol	(on disk)
H-1. Office of Inspector General Provider Self-Disclosure Protocol (63 Fed. Reg. 58,399–58,403 (Oct. 30, 1998))	(on disk)
H-2. Open Letter to Health Care Providers from HHS Inspector General on the Provider Self-Disclosure Protocol (Apr. 15, 2008)	(on disk)
H-3. Open Letter to Health Care Providers from HHS Inspector General on the Provider Self-Disclosure Protocol, Refined (Mar. 15, 2009)	(on disk)
Appendix I: Office of Inspector General Compliance Materials and Related Industry Documents	(on disk)
I-1.1. OIG Compliance Program Guidance for Hospitals (63 Fed. Reg. 8987–8998 (Feb. 23, 1998))	(on disk)
I-1.2. OIG Supplemental Compliance Program Guidance for Hospitals (70 Fed. Reg. 4858 (Jan. 31, 2005))	(on disk)
I-2. OIG Compliance Program Guidance for Individual and Small Group Physician Practices (65 Fed. Reg. 59,434–59,452 (Oct. 5, 2000))	(on disk)
I-3.1. OIG Compliance Program Guidance for Pharmaceutical Manufacturers (Apr. 2003)	(on disk)
I-3.2. PhRMA Code on Interactions With Healthcare Professionals (Jan. 2009)	(on disk)
I-3.3. Advanced Med. Tech. Ass’n, Code of Ethics on Interactions With Health Care Professionals (Dec. 18, 2008)	(on disk)
I-4. Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health & Human Services and Vencor, Inc. (July 2000)	(on disk)
I-5. Draft OIG Compliance Program Guidance for Recipients of PHS Research Awards (Nov. 2005)	(on disk)
I-6. Draft OIG Supplemental Compliance Program Guidance for Nursing Facilities, 74 Fed. Reg. 20,680 (Apr. 16, 2008)	(on disk)
I-7. OIG Supplemental Compliance Program Guidance for Nursing Facilities, 75 Fed. Reg. 56,832 (Sept. 30, 2008)	(on disk)
Appendix J: Medicare Managed Care Materials	(on disk)
J-1. Contract with Eligible Medicare Advantage Organization for the Operation of a Medicare Advantage Coordinate Care Plan	(on disk)
J-2. Addendum to Medicare Managed Care Contract for the Operation of a Voluntary Medicare Prescription Drug Plan	(on disk)
J-3. Contract with Approved Entity for the Operation of a Voluntary Medicare Prescription Drug Plan	(on disk)
J-4. Medicare Improvements for Patients and Providers Act (MIPPA), Pub. L. No. 11-275 (July 15, 2008)	(on disk)
J-5. Revisions to the Medicare Advantage and Prescription Drug Benefit Programs, 73 Fed. Reg. 28,556 (May 16, 2008)	(on disk)
Appendix K: Electronic Technology Materials	(on disk)
K-1. American Recovery and Reinvestment Act of 2009, Health Information Technology for Economic and Clinical Health Act (HITECH Act), §13001 <i>et seq.</i> , Pub. L. No. 111-05, 123 Stat. 115 (Feb. 17, 2009)	(on disk)

Appendix L: PPACA Materials		(on disk)
L-1. The Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (signed Mar. 23, 2010) (PPACA)		(on disk)
L-2. Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, 124 Stat. 1029 (signed Mar. 30, 2010) (Reconciliation Act)		(on disk)
L-3. Congressional Research Service, Medicare Provisions in PPACA (P.L. 111-148) (Apr. 2010)		(on disk)
Table of Cases	873	523
Index	885	—